These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 7407790)

  • 41. Rank-Minimization for balanced assignment of subjects in clinical trials.
    Stigsby B; Taves DR
    Contemp Clin Trials; 2010 Mar; 31(2):147-50. PubMed ID: 20004741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynamic balancing randomization in controlled clinical trials.
    Heritier S; Gebski V; Pillai A
    Stat Med; 2005 Dec; 24(24):3729-41. PubMed ID: 16320277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current research in statistical methodology for clinical trials.
    Meier P
    Biometrics; 1982 Mar; 38 Suppl():141-53. PubMed ID: 7046819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of randomization techniques for clinical trials with data from the HOMERUS-trial.
    Verberk WJ; Kroon AA; Kessels AG; Nelemans PJ; Van Ree JW; Lenders JW; Thien T; Bakx JC; Van Montfrans GA; Smit AJ; Beltman FW; De Leeuw PW
    Blood Press; 2005; 14(5):306-14. PubMed ID: 16257877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of restricted sequential design in a clinical protocol.
    Thompson EI
    Cancer Treat Rep; 1980; 64(2-3):399-403. PubMed ID: 7407776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statistical inference and the design of clinical trials.
    Berry DA
    Biomedicine; 1980 Feb; 32(1):4-7. PubMed ID: 7370380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Randomization and stratification in clinical research (author's transl)].
    Fei LM; Zeng XJ
    Zhonghua Yi Xue Za Zhi; 1981 Jun; 61(6):331-4. PubMed ID: 6796230
    [No Abstract]   [Full Text] [Related]  

  • 48. [Introduction of dynamic balancing randomization method and its application].
    Liu ZL; Liu BQ; Li LH; Liu JP
    Zhong Xi Yi Jie He Xue Bao; 2011 Mar; 9(3):246-51. PubMed ID: 21419076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proceedings of the Symposium on Designs for Clinical Cancer Reseach. Discussion I: Basic design considerations.
    Cancer Treat Rep; 1980; 64(2-3):411-7. PubMed ID: 7407778
    [No Abstract]   [Full Text] [Related]  

  • 50. Proceedings of the Symposium on Designs for Clinical Cancer Research. Summary views: A statistician's perspective.
    Cox DR
    Cancer Treat Rep; 1980; 64(2-3):533-5. PubMed ID: 7407795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Balance and randomness in sequential clinical trials: the dominant biased coin design.
    Antognini AB; Zagoraiou M
    Pharm Stat; 2014; 13(2):119-27. PubMed ID: 24443205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A generic minimization random allocation and blinding system on web.
    Cai H; Xia J; Xu D; Gao D; Yan Y
    J Biomed Inform; 2006 Dec; 39(6):706-19. PubMed ID: 16616696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crossover and self-controlled designs in clinical research.
    Louis TA; Lavori PW; Bailar JC; Polansky M
    N Engl J Med; 1984 Jan; 310(1):24-31. PubMed ID: 6689736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studywise minimization: a treatment allocation method that improves balance among treatment groups and makes allocation unpredictable.
    Perry M; Faes M; Reelick MF; Olde Rikkert MG; Borm GF
    J Clin Epidemiol; 2010 Oct; 63(10):1118-22. PubMed ID: 20304606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical trials in psychosocial medicine: methodologic and statistical considerations. Part I. Introduction.
    Schmale AH
    Cancer Treat Rep; 1980; 64(2-3):441-3. PubMed ID: 7407782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On constrained balance randomization for clinical trials.
    Titterington DM
    Biometrics; 1983 Dec; 39(4):1083-6. PubMed ID: 6671120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
    Halabi S
    Urol Oncol; 2008; 26(3):300-7. PubMed ID: 18452825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical trials in urology: how many patients are required to achieve statistically significant results?
    Parazzini F; Colli E; Chatenoud L; Malvezzi M; Olivieri L; Montorsi F; La Vecchia C
    BJU Int; 2005 Apr; 95(5):717-22. PubMed ID: 15784083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Statistical methods in the evaluation of the therapeutic efficacy--their problems and solutions].
    Tominaga S
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1873-81. PubMed ID: 6764094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Kos statement on randomization. First International Meeting, Kos 1986; Second International Meeting, Paris 1987.
    Biomed Pharmacother; 1988; 42(3):167. PubMed ID: 3179401
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.